AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Status:
Recruiting

Trial end date:
2025-03-25

Target enrollment:

Participant gender:

The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of AMG 757 in combination with AMG 404.

Phase 1

Amgen